C E Walsh1, K Workowski2, N A Terrault3, P E Sax4, A Cohen5, C L Bowlus6, A Y Kim7, R H Hyland8, B Han8, J Wang8, L M Stamm8, D M Brainard8, J G McHutchison8, A von Drygalski9, F Rhame10, M W Fried11, P Kouides12, G Balba13, K R Reddy14. 1. Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY, USA. 2. Emory University, Atlanta, GA, USA. 3. University of California at San Francisco, San Francisco, CA, USA. 4. Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 5. Newark Beth Israel Medical Center, Barnabas Health, Newark, NJ, USA. 6. University of California at Davis, Davis, CA, USA. 7. Massachusetts General Hospital, Boston, MA, USA. 8. Gilead Sciences Inc., Foster City, CA, USA. 9. University of California at San Diego, San Diego, CA, USA. 10. Abbott Northwestern Hospital, Minneapolis, MN, USA. 11. University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 12. The Mary M. Gooley Hemophilia Center, Rochester, NY, USA. 13. MedStar Georgetown University Hospital, Washington, DC, USA. 14. University of Pennsylvania, Philadelphia, PA, USA.
Abstract
INTRODUCTION: Chronic hepatitis C virus (HCV) infection is prevalent among patients with inherited bleeding disorders and is a leading cause of mortality in those with haemophilia. AIM: We evaluated the efficacy and safety of ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic HCV genotype 1-4 infection and an inherited bleeding disorder. METHODS: Ledipasvir-sofosbuvir was administered for 12 weeks to patients with genotype 1 or 4 infection and for 12 or 24 weeks to treatment-experienced cirrhotic patients with genotype 1 infection. Patients with genotype 2 and 3 infection received sofosbuvir plus ribavirin for 12 and 24 weeks respectively. RESULTS: The majority of the 120 treated patients had a severe bleeding disorder (55%); overall, 65% of patients had haemophilia A and 26% of patients had haemophilia B; 22% were HIV coinfected. Sustained virologic response at 12 weeks posttreatment was 99% (98/99) in patients with genotype 1 or 4 infection; 100% (5/5) in treatment-experienced cirrhotic patients with genotype 1 infection; 100% (10/10) in patients with genotype 2 infection; and 83% (5/6) in patients with genotype 3 infection. There were no treatment discontinuations due to adverse events (AEs). The most frequent non-bleeding AEs were fatigue, headache, diarrhoea, nausea and insomnia. Bleeding AEs occurred in 22 patients, of which all but one were considered unrelated to treatment. CONCLUSION: Treatment with ledipasvir-sofosbuvir for patients with HCV genotype 1 or 4 infection or sofosbuvir plus ribavirin for patients with genotype 2 or 3 infection was highly effective and well tolerated among those with inherited bleeding disorders.
INTRODUCTION:Chronic hepatitis C virus (HCV) infection is prevalent among patients with inherited bleeding disorders and is a leading cause of mortality in those with haemophilia. AIM: We evaluated the efficacy and safety of ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic HCV genotype 1-4 infection and an inherited bleeding disorder. METHODS:Ledipasvir-sofosbuvir was administered for 12 weeks to patients with genotype 1 or 4 infection and for 12 or 24 weeks to treatment-experienced cirrhotic patients with genotype 1 infection. Patients with genotype 2 and 3 infection received sofosbuvir plus ribavirin for 12 and 24 weeks respectively. RESULTS: The majority of the 120 treated patients had a severe bleeding disorder (55%); overall, 65% of patients had haemophilia A and 26% of patients had haemophilia B; 22% were HIV coinfected. Sustained virologic response at 12 weeks posttreatment was 99% (98/99) in patients with genotype 1 or 4 infection; 100% (5/5) in treatment-experienced cirrhotic patients with genotype 1 infection; 100% (10/10) in patients with genotype 2 infection; and 83% (5/6) in patients with genotype 3 infection. There were no treatment discontinuations due to adverse events (AEs). The most frequent non-bleeding AEs were fatigue, headache, diarrhoea, nausea and insomnia. Bleeding AEs occurred in 22 patients, of which all but one were considered unrelated to treatment. CONCLUSION: Treatment with ledipasvir-sofosbuvir for patients with HCV genotype 1 or 4 infection or sofosbuvir plus ribavirin for patients with genotype 2 or 3 infection was highly effective and well tolerated among those with inherited bleeding disorders.
Authors: Tiago Pereira Guedes; Mónica Garrido; Ricardo Kuttner Magalhães; Teresa Moreira; Marta Rocha; Luís Maia; José Manuel Ferreira; Sara Morais; Isabel Pedroto Journal: GE Port J Gastroenterol Date: 2020-09-29
Authors: Elise J Smolders; Anouk M E Jansen; Peter G J Ter Horst; Jürgen Rockstroh; David J Back; David M Burger Journal: Clin Pharmacokinet Date: 2019-10 Impact factor: 6.447
Authors: Patricia A M Kracht; Faydra I Lieveld; Linde M Amelung; Carina J R Verstraete; Eveline P Mauser-Bunschoten; Joep de Bruijne; Peter D Siersema; Andy I M Hoepelman; Joop E Arends; Karel J van Erpecum Journal: Infect Dis Ther Date: 2018-08-03
Authors: Christian Qvigstad; Robert Campbell Tait; Stephan Rauchensteiner; Erik Berntorp; Philippe de Moerloose; Roger E Schutgens; Pål Andre Holme Journal: Medicine (Baltimore) Date: 2018-09 Impact factor: 1.889